Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA

Abstract

Plasma genotyping by NGS is an effective method for detecting <i>ALK</i> fusions and <i>ALK</i> mutations in patients progressing on ALK TKIs. The correlation between plasma <i>ALK</i> mutations and response to distinct ALK TKIs highlights the potential for plasma analysis to guide selection of ALK-directed therapies.